Arcutis Biotherapeutics Inc (ARQT) Company Profile & Statistics

Arcutis Biotherapeutics Inc
ARQT
(Nasdaq - US)
N/A
9.18
+0.06 (+0.66%)
in:usd•As of: May 17, 2024 15:59 UTC -4
Open
9.11
High
9.30
Low
8.56

About Arcutis Biotherapeutics Inc

CEO

Todd Franklin Watanabe

Headquarters

3027 townsgate road, suite 300

westlake village, ca 91361, united states

Auditor

Ernst & Young LLP

Employees

296

Share Holders

Website

www.arcutis.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.

Arcutis Biotherapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	1.06B
Enterprise Value	1.07B
Enterprise Value/EBITDA (ttm)	-5.33
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	4.68
Price to Sales (ttm)	9.92
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	89.69%
Operating Margin (ttm)	-204.35%
Profit Margin (ttm)	-511.68%
Return on Equity (ttm)	-197.28%
Return on Invested Capital (ttm)	-74.51%
Return on Assets (ttm)	-60.67%

Income Statement

Revenue (ttm)	106.39M
Revenue Per Share (ttm)	0.92
Gross Profit (ttm)	98.93M
EBITDA (ttm)³	-201.50M
Net Income Avi to Common (ttm)	-217.42M
Diluted EPS (ttm)	-2.93

Share Statistics

Beta (5Y Monthly)	1.18
52-Week Change	-3.06%
S&P500 52-Week Change	26.51%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	115.76M
Dividend Yield	0.00%
Float ⁴	91.80M
% Held by Insiders	20.70%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	404.48M
Total Cash Per Share (mrq)	3.49
Total Debt (mrq)	202.80M
Total Debt/Equity (mrq)	90.16%
Current Ratio (mrq)	9.89%
Quick Ratio (mrq)	6.80%
Book Value Per Share (mrq)	1.95

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.28
Free Cash Flow (ytd)	-31.60M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Arcutis Biotherapeutics Inc

Trade With A Regulated Broker